![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ANADYS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO
ANADYS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO
July 7, 2005
Anadys Pharmaceuticals, a biopharmaceutical company committed to the discovery, development and commercialization of novel anti-infective medicines, announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act for the Company's exclusive global license and co-development agreement with Novartis. In conjunction with the HSR clearance, Anadys will receive the initial license payment of $20 million from Novartis.
PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=254243)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct